1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Northeast Pharmaceutical Group Co., Ltd. Class A

Northeast Pharmaceutical Group Co., Ltd. Class A

SSZSE:000597
4.49
CNY
0.00
(0.00%)
0.15EPS
22.80P/E
6.05BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.22
4.93
3.64
4.56
5.37
6.16
6.14
6.02
5.76
6.29
5.75
5.31
4.9
4.81
Basic EPS, GAAP
-0.23
0.1
-0.36
0.02
0.11
0.16
0.13
0.01
0.07
0.25
0.25
0.29
0.18
0.19
Free Cash Flow per Basic Share
-0.97
-0.55
-0.23
0.2
-0.68
-0.23
0.09
0.14
0.44
0.62
0.25
0.42
0.7
- -
Dividend per Share
0.26
0.23
0.17
0.15
0.15
0.14
0.1
0.1
0.12
0.08
0.15
0.15
0.14
0.18
Book Value per Share
2.03
2.53
2.17
2.2
2.31
2.74
2.83
2.95
3.07
3.18
3.49
3.72
3.87
3.88
Tangible Book Value per Share
0.96
1.77
1.37
1.37
1.41
2.05
2.12
2.23
2.35
2.58
2.9
2.63
2.78
2.79
Basic Weighted Avg Shares
741
879
1,053
1,056
1,057
1,212
1,338
1,226
1,415
1,401
1,434
1,413
1,445
1,420
Sales/Revenue/Turnover
3,871
4,333
3,834
4,814
5,676
7,467
8,220
7,384
8,145
8,809
8,243
7,503
7,075
6,835
Operating Margin (%)
-0.85
4.25
-5.13
4.06
6.44
6.32
5.45
4.41
4.37
5.15
7.84
8.84
7.05
7.05
Depreciation Expense
148
171
213
317
326
323
340
481
551
561
575
572
542
- -
Net Income, GAAP
-167
87
-384
24
119
195
174
12
99
350
358
410
260
264
Effective Tax Rate (%)
- -
20.74
- -
29.61
9.9
5.79
23.99
88.21
20.57
32.03
22.98
28.73
28.64
24.29
Profit Margin (%)
-4.31
2.01
-10.02
0.49
2.1
2.61
2.12
0.17
1.22
3.98
4.35
5.46
3.68
3.86
Working Capital
-786
-275
-733
106
-469
-1,064
-2,020
-1,772
-1,399
-493
215
390
969
1,052
LT Debt
100
100
180
600
235
874
150
256
218
256
181
30
174
78
Total Equity
1,599
2,761
2,401
2,434
2,548
3,588
3,918
4,122
4,290
4,713
5,159
5,570
5,669
5,652
Return on Invested Capital (%)
- -
0.11
- -
0.02
1.74
1.06
2.14
0.24
2
6.67
5.52
5.85
3.09
2.59
Return on Capital (%)
- -
4.17
- -
2.13
4.58
4.82
3.63
0.36
2.57
5.55
5.6
6.07
4.49
4.62
Return on Common Equity (%)
-10.54
4.18
-15.52
1.03
5.01
6.62
4.78
0.31
2.44
8.05
7.51
7.95
4.79
4.85

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,972
1,744
1,798
LT Borrowings
155
155
66
LT Finance Leases
20
19
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,427
1,427
1,427
Market Capitalization
7,449
7,606
6,050

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,532
8,340
8,440
Cash, Cash Equivalents & STI
3,602
3,970
4,170
Accounts Receivable, Net
1,733
2,203
2,205
Inventories
1,182
1,234
1,351
Total Current Liabilities
6,564
7,253
7,388
Payables & Accruals
- -
- -
- -
ST Debt
1,972
1,744
1,798
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.44%
6.63%
1.79%
Free Cash Flow
-41.09%
76.99%
68.29%
Net Income, GAAP
119.6%
188.35%
-36.54%
Sales/Revenue/Turnover
7.23%
-0.53%
-5.7%
Total Cash Common Dividend
5.36%
17.74%
-4.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,940
2,228
1,965
1,369
7,503
2025
1,947
1,905
- -
1,597
7,075
2026
2,006
1,327
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.07
0.04
0.14
0.29
2025
0.03
0.07
- -
0.06
0.18
2026
0.02
0.04
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.11
0.01
0.01
0.15
2025
0.02
0.11
- -
-0.01
0.14
2026
0.01
0.06
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong Gang Cai
Full Time Employees
5,727
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.8 Kunminghu Street Shenyang LI China 110027
IPO Date
May 23, 1996
Website
nepharm.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) manufactures and sells chemical pharmaceuticals, including active pharmaceutical ingredients and formulations; engages in pharmaceutical commerce through wholesale and chain distribution; provides pharmaceutical engineering services such as design, manufacturing, and installation; and develops biomedicine products encompassing biological diagnostic reagents, cell therapy, and innovative biologics, primarily in China with exports to over 100 countries. The company produces ten major series of high-quality drugs, including vitamin series such as vitamin C, B1, and B6; anti-infection products like fosfomycin, azithromycin, and chloramphenicol; reproductive system and sex hormone products comprising carboprost and dapoxetine hydrochloride; nervous system drugs including piracetam; anti-AIDS medications such as zidovudine; digestive system products like sucralfate and berberine; cardiovascular and cerebrovascular medicines; analgesic and cough relief drugs; urinary system drugs; and big health field offerings, supported by over 400 chemical raw materials, intermediates, and formulations under trademarks "Northeast" and "Fumeixin". Founded in 1946 as Northeast Pharmaceutical General Factory and listed on the Shenzhen Stock Exchange in 1996, Northeast Pharmaceutical Group Co., Ltd. maintains headquarters in Shenyang, Liaoning Province, China, with production bases spanning 910,000 square meters for APIs and 180,000 square meters for formulations, and operates as a subsidiary of Liaoning Fangda Group Industrial Co., Ltd. In 2024, the company acquires 70% equity in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately CNY 187 million to enter solid tumor cell therapy, leveraging ADC, CAR-T, TCR-T, and TCR protein platforms for innovative biologics; deepens strategic cooperation with institutions like the Chinese Academy of Sciences; and advances cross-generational innovation in biological drugs while optimizing generic drug portfolios.